Consumption of similar biological medicinal products (biosimilars) in the Czech Republic Author: Kristýna Vlachová Supervisor: PharmDr. Pavel Horký, Ph.D. Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University Introduction: Biological treatment is a modern alternative to chemotherapeutics especially in patients with difficult-to-treat diseases of autoimmune origin, as well as patients with other diseases. Biosimilars are biological medicinal products similar to the original biologics. They are increasingly used in a wide range of indications. A new biosimilar drug is registered every year, as soon as the patent protection of the original biologics expires. The assumption is that the consumption of biosimilars and biologists in the Czech Republic will increase. The question is to what extent it will increase and what is the market share of biosimilars. Objective: The aim of the diploma thesis was to analyze the consumption of biosimilar epoetin, adalimumab, infliximab and etanercept in the Czech Republic in 2010-2020. Methods: A retrospective analysis of the consumption of biosimilars epoetin, adalimumab, infliximab and etanercept was performed from 1. 1. 2010 to 31. 12. 2020. The selection of specific biosimilars was made on the basis of their wide...
| Identifer | oai:union.ndltd.org:nusl.cz/oai:invenio.nusl.cz:448564 |
| Date | January 2021 |
| Creators | Vlachová, Kristýna |
| Contributors | Horký, Pavel, Zimčíková, Eva |
| Source Sets | Czech ETDs |
| Language | Czech |
| Detected Language | English |
| Type | info:eu-repo/semantics/masterThesis |
| Rights | info:eu-repo/semantics/restrictedAccess |
Page generated in 0.0022 seconds